Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an intravenous iron supplement presented as an injection solution for intravenous infusion. It provides elemental iron for incorporation into hemoglobin and supports erythropoiesis, addressing iron deficiency anemia in adults, including cases related to chronic kidney disease, inflammatory bowel disease, and post‑operative or postpartum periods.

GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Monofer is used to treat iron deficiency anemia by replenishing body iron stores. - Iron deficiency anemia (adult): restores hemoglobin levels and improves fatigue and functional capacity. - Chronic kidney disease‑associated anemia: supplies iron needed for erythropoiesis in patients with reduced renal function. - Inflammatory bowel disease‑related anemia: corrects iron loss due to intestinal inflammation. - Post‑operative or postpartum anemia: rapidly repletes iron after surgery or childbirth.

Ferric derisomaltose may be associated with a range of adverse reactions following intravenous infusion.

Common Side Effects: - Hypersensitivity reactions (rash, pruritus): mild skin manifestations at the infusion site. - Nausea or vomiting: gastrointestinal discomfort occurring during or shortly after infusion. - Headache: transient headache reported by some patients. - Transient increase in serum phosphate: mild, self‑limiting change in phosphate levels.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity: potentially life‑threatening allergic reaction requiring immediate medical intervention. - Hypotension or cardiovascular collapse: sudden drop in blood pressure during infusion. - Iron overload: excessive iron accumulation with long‑term high dosing. - Acute kidney injury: rare renal impairment observed post‑infusion.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events. - Assess iron status: confirm iron deficiency before initiating therapy. - Monitor for hypersensitivity: observe patient during and after infusion for allergic signs. - Avoid rapid infusion rates: follow recommended administration speed to reduce adverse events. - Use caution in patients with active infections: iron may promote bacterial growth. - Renal function monitoring: evaluate kidney function in patients with pre‑existing renal disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ferric derisomaltose can interact with other agents that affect iron metabolism or renal function.

Major Interactions (Avoid): - Concurrent use of other intravenous iron products: risk of iron overload. - Co‑administration with erythropoiesis‑stimulating agents without iron monitoring: may exacerbate hypertension.

Moderate Interactions (Monitor Closely): - Oral iron supplements taken within 2 hours: may reduce efficacy of the IV product. - Antacids or proton‑pump inhibitors: may alter infusion site reactions. - Nephrotoxic drugs (e.g., methoxyflurane): monitor renal function closely.